Physiologically based pharmacokinetics of KNI-272, a tripeptide HIV-1 protease inhibitor.

@article{Kiriyama1999PhysiologicallyBP,
  title={Physiologically based pharmacokinetics of KNI-272, a tripeptide HIV-1 protease inhibitor.},
  author={A Kiriyama and T Nishiura and H Yamaji and Kanji Takada},
  journal={Biopharmaceutics & drug disposition},
  year={1999},
  volume={20 4},
  pages={199-205}
}
The effects of dose on the pharmacokinetic characteristics of KNI-272 were evaluated in rats after intravenous (iv) administration. The plasma kinetics of KNI-272 were dose-independent within a dose range of 1.0 to 10.0 mg/kg. However, when the dose was increased to 50.0 mg/kg, the area under the plasma concentration-time curve (AUC)/dose significantly increased and the total plasma clearance (Cl(tot)) significantly decreased, possibly due to saturation of hepatic metabolism. On the other hand… CONTINUE READING